Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Baseline steroid use may decrease efficacy of checkpoint inhibitors

Arbour KC et al. J Clin Oncol. 2018 Aug 20. doi: 10.1200/JCO.2018.79.0006.

Key clinical point: Immune checkpoint inhibitors may be less effective if the patient is receiving corticosteroids at the time treatment is started.

Major finding: Corticosteroid use at the time of PD-1/PD-L1 blockade was associated with decreased progression-free survival (hazard ratio, 1.31; P = .03) and overall survival (HR, 1.66; P less than .001) in multivariate analysis.

Study details: Retrospective analysis of 640 patients treated with atezolizumab, durvalumab, nivolumab, or pembrolizumab at Memorial Sloan Kettering Cancer Center or Gustave Roussy Cancer Center.

Disclosures: The authors reported disclosures related to Amgen, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Genentech, Janssen Pharmaceuticals, MedImmune, Merck, Mirati Therapeutics, Pfizer, Roche, Shattuck Labs, and Syndax, among others.

Read the article.


Arbour KC et al. J Clin Oncol. 2018 Aug 20. doi: 10.1200/JCO.2018.79.0006.

This Week's Must Reads

Program reduces ER admissions and inpatient costs, Mendenhall M et al. Quality Care Symposium, Abstract 30

Pain severity decreased over time with app, Kamdar MM et al. PallOnc 2018, Abstract 76

National health care spending growth slowed to 3.9% in 2017 , Martin A et al. Health Affairs. 2018. doi: 10.1377/hlthaff.2018.05085

Federal proposal aims to move doctors back to face-to-face interventions, Office of the National Coordinator for Health IT

Must Reads in Immuno-oncology

Lenvatinib plus pembrolizumab shows promising activity in NSCLC, Brose M et al. SITC 2018, Abstract P392

Nivolumab boosts survival over chemo for advanced melanoma, Ascierto PA et al. JAMA Oncol. 2018 Oct 25. doi: 10.1001/jamaoncol.2018.4514

Checkpoint inhibitor combo continues to show benefit for advanced melanoma, Hodi FS et al. Lancet Oncol. 2018 Oct 22. doi: 10.1016/S1470-2045(18)30700-9